Navigating the challenges of bringing cell and gene therapies to market
The path from novel science to a functional business model is rarely a straight one. Besides regulatory hurdles, there remain…
The path from novel science to a functional business model is rarely a straight one. Besides regulatory hurdles, there remain…
As the pharma world embraces digitisation with electronic consent (eConsent) forms, wearable devices, and artificial intelligence enhancing the accuracy of…
T-cell production has come a long way from the days of lengthy manual processes in labs with several technicians required.…
The Covid-19 pandemic did much to expose the inefficiencies in clinical supply chains, revealing inconsistencies in inventory management practices and…
The progress of advanced therapeutics in recent years, especially in oncology, have been so promising many are starting to use…
The global healthcare sector has witnessed both unprecedented challenges and achievements over the past few years, most notably during the…
Despite more than 18% of the global population living in Africa, the continent typically hosts a relatively small percentage of…
By 2029, the global cell and gene therapy market is projected to be worth more than $81bn, according to GlobalData’s…
HPAPIs offer crucial advantages in treatments for serious and complex diseases, such as cancer and autoimmune disorders. Designed to target…
Recent years have seen a promising trend: the application of technology to revolutionise patient engagement and retention strategies. From mobile…